Immune checkpoint inhibitors (ICI), either alone for selected patients (Programmed Cell Death-ligand 1 (PD-L1) ≥ 50% EU and PD-L1 ≥ 1% in USA), or in combination with chemotherapy, have become the standard of care (SOC) for most good performance status (PS) patients with metastatic disease [5]. This evidence concerns the gene CD274 and metastatic neoplasm.